Clinical Trial Update: Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Tumors [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating radiolabeled monoclonal antibody therapy for primary or metastatic brain tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Brain Tumors

Drugs mentioned

• Radiolabeled Monoclonal Antibody Therapy

Snippet

Sponsor: Duke University | Conditions: Brain and Central Nervous System Tumors, Metastatic Cancer | Phase 1, Phase 2 | Status: COMPLETED